Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SmithKline Beecham's Kytril

Executive Summary

Comparative trial of Kytril (granisetron) to Glaxo's Zofran (ondansetron) in 533 patients with lung cancer found no significant differences in "anti-emetic efficacy between Kytril 10 mcg/kg versus Zofran .15 mg/kg, SB says. The study, presented at the 7th World Conference on Lung Cancer, is "the first head-to- head trial of Kytril injection. and Zofran injection at dosing regimens marketed in the U.S.," SB declares. In the full study of 992 patients with all types of cancer, no differences in side effects were seen
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024719

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel